Entia Biosciences, Inc. (ERGO) Stock

About Entia Biosciences, Inc.

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.

Entia Biosciences, Inc. (ERGO) stock trades at $0.00 with a market capitalization of $6732. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.03. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades 100.0% below its 52-week high.

On profitability, Entia Biosciences, Inc. generates a return on equity (ROE) of 50.00% — well above the market average, a sign of a high-quality business, return on capital employed of 70.05%, an operating margin of -439.75%, a net profit margin of -554.75%.

Official website: www.roxanaradu.com